Additionally, IDH3A has been found to be upregulated in HCC cell lines treated with a combination of celecoxib and sorafenib, both of which exhibit synergistic anti-proliferative and pro-apoptotic effects on HCC cells (139). Here, IDH3A is linked to hepatocellular carcinoma.